Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 39.00
Ask: 41.00
Change: 0.75 (1.91%)
Spread: 2.00 (5.128%)
Open: 38.50
High: 40.00
Low: 38.50
Prev. Close: 39.25
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Chief Financial Officer

1 May 2019 07:00

RNS Number : 6279X
Venture Life Group PLC
01 May 2019
 

1 May 2019

Venture Life Group plc

("Venture Life" or the "Group")

Appointment of Chief Financial Officer

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, today announces that it has appointed Andrew Waters, FCA, to the Board of Venture Life as Chief Financial Officer with immediate effect. 

Andrew has been working closely with the Board since February 2019 after the departure of former CFO, Adrian Crockett, earlier this year. Andrew is a Chartered Accountant having previously worked at PWC and then GlaxoSmithKline plc, where he spent 16 years in various financial and business management positions. Following this, Andrew co-founded two businesses, Cubase Consulting Ltd and Infirst Healthcare Ltd, which he led through three successful funding rounds, raising in excess of £40 million from private equity.

Dr Lynn Drummond, Chair of Venture Life, said: "We are delighted to welcome Andrew to the Board of Venture Life. Andrew brings a range of skills to the team to support the ambitious plans we have for the business over the coming years. I am confident Andrew will be a valuable and complementary addition to the executive team."

 

Disclosures required by Schedule 2(g) of the AIM Rules for Companies

In the past 5 years, Mark Andrew Waters, aged 52, has held the following positions where he was acting in the capacity of a Director:

Current Directorships:

Cubase Consulting Ltd

AW Chartered Accountant

Past Directorships:

Infirst Healthcare Ltd

Infirst Healthcare Inc (USA)

Infirst Healthcare Ltd (Ireland) (formerly Immunocopea Ltd)

Respicopea Holding Ltd

 

Andrew Waters does not have any interest in the ordinary shares of the Company.

There are no further disclosures to be made pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

Venture Life Group PLC

+44(0) 1344 578004

Jerry Randall, Chief Executive Officer

Cenkos Securities Ltd (Nomad and Broker)

+44(0)20 7397 8900

Mark Connelly / Stephen Keys / Cameron MacRitchie (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)

 

 Alma PR

 +44(0)20 3405 0208

 Rebecca Sanders-Hewett / Hilary Buchanan / Helena Bogle / Jessica Joynson

 

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAZMGFDKGVGLZM
Date   Source Headline
7th Oct 201910:57 amRNSHolding(s) in Company
20th Sep 20197:00 amRNSHalf-year Report - Amendment
19th Sep 20197:00 amRNSInterim Results
17th Jul 20197:00 amRNSCommercial update
11th Jul 20193:33 pmRNSDirector/PDMR Shareholding
8th Jul 20195:02 pmRNSHolding(s) in Company
25th Jun 20198:44 amRNSDirector/PDMR Shareholding
3rd Jun 201911:36 amRNSResult of AGM
17th May 20194:35 pmRNSPrice Monitoring Extension
1st May 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSFinal Results
26th Mar 20195:17 pmRNSHolding(s) in Company
20th Mar 20197:00 amRNSNotice of Results Update
29th Jan 20197:00 amRNSTrading and Commercial Update
5th Dec 20183:26 pmRNSHolding(s) in Company
5th Dec 20188:12 amRNSHolding(s) in Company
23rd Nov 20187:00 amRNSChange of adviser and directorate update
15th Nov 20187:00 amRNSCommercial update
20th Sep 20187:01 amRNSDirectorate Change
20th Sep 20187:00 amRNSHalf-year Report
16th Aug 20187:00 amRNSTrading update & notice of interim results
13th Aug 201812:17 pmRNSHolding(s) in Company
8th Aug 20182:15 pmRNSHolding(s) in Company
8th Aug 20187:00 amRNSCompletion of Placing and Acquisition
7th Aug 20184:54 pmRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201811:24 amRNSHolding(s) in Company
7th Aug 201810:10 amRNSHolding(s) in Company
6th Aug 201811:51 amRNSResult of General Meeting
23rd Jul 20184:00 pmRNSHolding(s) in Company
20th Jul 20187:00 amRNSPlacing, proposed acquisition and notice of GM
20th Jul 20187:00 amRNSAppointment of Joint Broker
19th Jul 20183:38 pmRNSHolding(s) in Company
18th Jun 20187:00 amRNSIncreased distribution of UltraDEX in Boots, UK
4th Jun 20187:00 amRNSLloyds Pharmacy to list UltraDEX in UK
23rd May 201812:29 pmRNSResult of AGM
21st May 20187:00 amRNS'1000 Companies to Inspire Britain' 2018 report
9th May 20187:00 amRNSAlliance Pharma contract expansion and extension
8th May 20182:54 pmRNSHolding(s) in Company
30th Apr 20187:00 amRNSUltraDEX update
17th Apr 20187:00 amRNSDirector/PDMR Shareholding
5th Apr 20187:00 amRNSDirector/PDMR Shareholding
27th Mar 20187:00 amRNSDirector/PDMR Shareholding
26th Mar 20187:00 amRNS2018 LTIP and Grant of Options to PDMRs
22nd Mar 20187:00 amRNSFinal Results
5th Mar 20187:00 amRNSNotice of analyst & investor results briefings
16th Feb 20187:00 amRNSInvestor presentation
13th Feb 20187:00 amRNSCommerical update
31st Jan 20187:00 amRNSTrading update
8th Jan 20187:00 amRNSEuropean Business Awards 'Ones to Watch List'

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.